Alphatec Holdings, Inc. (ATEC) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $8.16 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 33.0): -1.5; Concentration risk — Supplier: Invibio.
Alphatec Holdings designs and sells spine surgery implants, instruments, biologics, and informatics technology exclusively for the spine market, generating $764.2 million in total revenue for fiscal 2025 — a 25% increase over 2024. Products are sold through a network of... Read more
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $8.16 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 33.0): -1.5; Concentration risk — Supplier: Invibio. Chart setup: Death cross but MACD improving, RSI 53. Score 5.6/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
About Alphatec Holdings, Inc.
About Alphatec Holdings, Inc.
Alphatec Holdings generated $764.2 million in total revenue for fiscal 2025, a 25% increase from $611.6 million in 2024, with surgical volume growing 22% and average revenue per surgery expanding 4%. Net sales of systems that include polyaxial pedicle screws represented 38% of total revenue, down from 40% in 2024. The company's flagship procedure, Prone TransPsoas (PTP), was launched in 2020 and has driven adoption among both lateral-experienced surgeons and new entrants to lateral surgery; complementary Lateral TransPsoas (LTP) and EOS imaging platforms were added in subsequent years. International operations are nascent, with early procedures in Australia and New Zealand beginning in 2022 and the first LTP surgery in Japan completed in late 2024.
Alphatec sells exclusively through a combination of exclusive independent sales agents and direct sales representatives who invoice hospitals after procedures; the go-to-market strategy relies on the "ATEC Experience" educational program that drove 20% growth in the surgeon user base in 2025. All implant manufacturing is outsourced to third-party suppliers; PEEK — a biocompatible plastic used in certain spacers — is sourced from Invibio, one of a limited number of companies approved to distribute PEEK in the U.S. for implantable devices, making Invibio the company's single-source supplier for this material. Competitors include Medtronic (Sofamor Danek), Johnson & Johnson (DePuy Spine), Zimmer Biomet, and Globus Medical, each with substantially greater financial resources.
Show full overview
Alphatec's dependence on Invibio as its single-source PEEK supplier exposes production continuity to a vendor relationship that cannot readily be replaced. The 10-K notes that supply interruptions from this limited or sole-sourced component could materially harm the company's ability to source manufactured products until a new supply source is found, and regulatory re-qualification of an alternative PEEK supplier would require FDA involvement. In May 2026, the company entered a new $300 million senior secured credit facility with JPMorgan Chase Bank, N.A. as administrative agent — a refinancing that extended the company's liquidity runway but left the underlying supplier dependency unchanged.
See also: Healthcare · Medical Devices
From Alphatec Holdings, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-15Recent Developments — Alphatec Holdings, Inc.
Latest news
- NEWS Alphatec (NASDAQ:ATEC) Hits New 52-Week Low - Should You Sell? - MarketBeat — MarketBeat negative
- NEWS Implied Volatility Surging for Alphatec Stock Options - TradingView — TradingView negative
- NEWS Alphatec Holdings Inc expected to post a loss of 2 cents a share - Earnings Preview - TradingView — TradingView negative
- NEWS Barclays Maintains Overweight on Alphatec Holdings, Lowers Price Target to $24 — benzinga May 7, 2026 positive
- NEWS Wells Fargo Maintains Overweight on Alphatec Holdings, Lowers Price Target to $14 — benzinga May 7, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductpolyaxial pedicle screw systems38%10-K Item 1A: 'Net sales of our systems that include polyaxial pedicle screws represented approximately 38%...our net sales for the years ended December 31, 2025'
- HIGHSupplierInvibio10-K Item 1A: 'in one case on a single source vendor, Invibio, to provide the raw materials used in the production of our products'
Material Events(8-K, last 90d)
- 2026-05-05Item 1.01MEDIUMOn May 1, 2026, Alphatec Holdings entered a senior secured credit agreement with JPMorgan Chase Bank, N.A. as admin agent, providing a $175 million Term Loan A and $125 million revolving credit facility, both maturing May 2031.SEC filing →
- 2026-05-05Item 1.02MEDIUMOn May 1, 2026, Alphatec terminated its prior credit facilities upon entry into the new JPMorgan Chase credit agreement. No specific prior agreement named in available excerpt.SEC filing →
- 2026-05-05Item 2.03LOWOn May 1, 2026, Alphatec Holdings created obligations under a $175 million Term Loan A and $125 million revolving credit facility with JPMorgan Chase Bank, N.A., maturing May 2031 subject to springing maturity provisions tied to 2030 convertible notes.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $8.16 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 33.0): -1.5; Concentration risk — Supplier: Invibio. Chart setup: Death cross but MACD improving, RSI 53. Prior stop was $7.60. Score 5.6/10, moderate confidence.
Take-profit target: $14.55 (+78.0% upside). Prior stop was $7.60. Stop-loss: $7.60.
Concentration risk — Supplier: Invibio; Leverage penalty (D/E 33.0): -1.5; Consecutive earnings misses (2).
Alphatec Holdings, Inc. trades at a P/E of N/A (forward 14.3). TrendMatrix value score: 9.1/10. Verdict: Sell.
18 analysts cover ATEC with a consensus score of 4.1/5. Average price target: $17.
What does Alphatec Holdings, Inc. do?Alphatec Holdings designs and sells spine surgery implants, instruments, biologics, and informatics technology...
Alphatec Holdings designs and sells spine surgery implants, instruments, biologics, and informatics technology exclusively for the spine market, generating $764.2 million in total revenue for fiscal 2025 — a 25% increase over 2024. Products are sold through a network of exclusive independent sales agents and direct representatives who invoice hospitals, with polyaxial pedicle screw systems representing 38% of net sales.